Monocyte procoagulant activity induced by in vivo administration of the OKT3 monoclonal antibody

Blood

Volumn 87, Issue 9, 1996, Pages 3768-3774

  Pradier, O ^a   Surquin, M ^a   Stordeur, P ^a   De Pauw, L ^a   Kinnaert, P ^a   Vereerstraeten, P ^a   Capel, P ^a   Goldman, M ^a   Abramowicz, D ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; CD11B ANTIGEN; GLYCOPROTEIN P 15095; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; OKT 3; PROCOAGULANT; THROMBOPLASTIN;

ARTICLE; BLOOD CLOTTING DISORDER; GENE CONTROL; HUMAN; HUMAN CELL; KIDNEY TRANSPLANTATION; MONOCYTE; PRIORITY JOURNAL; PROTEIN DETERMINATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS;

EID: 0029933170     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.9.3768.bloodjournal8793768     Document Type: Article

References (32)

1. Salmeroii A, Sanchez Madrid F, Ursa RM, Fresno M, Alarcon B: A conformarional epitope expressed upon association of CD3-epsilon with either CD3-delta or CD3-gamma is the main target for recognition by anti-CD3 monoclonal antibodies. J Immunol 147:3047, 1991
2. Anonymous: A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. Ortho Multicenter Transplant Study Group. N Engl J Med 313:337, 1985
3. Colonna JO, Goldstein LI, Brems JJ, Vargas, JH, Brill JE, Berquist WJ, Hiatt JR, Busuttil RW: A prospective study on the use of monoclonal anti-T3-cell antibody (OKT3) to treat steroid-resistant liver transplant rejection. Arch Surg 122:1120, 1987
4. Abramowicz D, Goldman M, De Pauw L, Vanherweghem JL, Kinnaert P, Vereerstraeten P: The long-term effects of prophylactic OKT3 monoclonal antibody in cadaver kidney transplantation - A single-center, prospective, randomized study Transplantation 54:433, 1992
5. Abramowicz D, Schandene L, Goldman M, Crusiaux A, Vereerstraeten P, De Pauw L, Wybran J, Kinnaert P, Dupont E, Toussaint P: Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 47:606, 1989
6. Chatenoud L, Ferran C, Reuter A, Legendre C, Gevaert Y, Kreis H, Franchimont P, Bach JF: Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma [corrected] [letter] [published erratum appears in N Engl J Med 321:63, 1989]. N Engl J Med 320:1420, 1989
7. Abramowicz D, Pradier O, Marchant A, Florquin S, De Pauw L, Vereerstraeten P, Kinnaert P, Vanherweghem JL, Goldman M: Induction of thromboses within renal grafts by high-dose prophylactic OKT3 [see comments]. Lancet 339:777, 1992
8. Raasveld MH, Hack CE, ten Berge IJ: Activation of coagulation and fibrinolysis following OKT3 administration to renal transplant recipients: Association with distinct mediators. Thromb Haemost 68:264, 1992
9. Pradier O, Marchant A, Abramowicz D, De Pauw L, Vereerstraeten P, Kinnaert P, Vanherweghem JL, Capel P, Goldman M: Procoagulant effect of the OKT3 monoclonal antibody: Involvement of tumor necrosis factor. Kidney Int 42:1124, 1992
10. Gregory SA, Edgington TS: Tissue factor induction in human monocytes. Two distinct mechanisms displayed by different alloantigen-responsive T cell clones. J Clin Invest 76:2440, 1985
11. Iitaka M, Iwatani Y, Row VV, Volpé R: Induction of monocyte procoagulant activity with OKT3 antibody. J Immunol 139:1617, 1987
12. Fan ST, Edgington TS: Coupling of the adhesive receptor CD11b/CD18 to functional enhancement of effector macrophage tissue factor response. J Clin Invest 87:50, 1991
13. Gailani D, Broze GJ: Factor-XI activation in a revised model of blood coagulation. Science 253:909, 1991
14. Ruf W, Edgington TS. An anti-tissue factor monoclonal antibody which inhibits TF.VIIa complex is a potent anticoagulant in plasma. Thromb Haemost 66:529, 1991
15. Pradier O, Abramowicz D, Capel P, Goldman M: Procoagulant properties of OKT3 at the monocyte level: Inhibition by pentoxifylline. Transplant Proc 25:39, 1993
16. Stordeur P, Schandené L, Durez P, Gerard C, Goldman M, Velu T: Spontaneous and cycloheximide-induced Interleukin-10 mRNA expression in human mononuclear cells. Mol Immunol 32:233, 1995
17. Alegre ML, Peterson LJ, Xu D, Sattar HA, Jeyarajah DR, Kowalkowski K, Thistlethwaite JR, Zivin RA, Jolliffe R, Bluestone JA: A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 57:1537, 1994
18. Alegre ML, Collins AM, Pulito VL, Brosius RA, Olson VC, Zivin RA, Knowles R, Thistlethwaite JR, Jolliffe LK, Bluestone JA: Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody. J Immunol 148:3461, 1992
19. Rao PE, Newman W, Meyer E, Fahmy B, Talle MA, Fanning VA: Identification of anti-CD3 antibodies that do not modulate antigen but induce mitogenesis and block the mixed lymphocyte reaction. Hum Immunol 33:275, 1992
20. Ferran C, Dautry F, Merite S, Sheehan K, Schreiber R, Grau R, Bach FJ, Chatenoud L: Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo. J Clin Invest 93:2189, 1994
21. Ogawa S, Clauss M, Kuwabara K, Shreeniwas R, Butura C, Koga S, Stern D: Hypoxia induces endothelial cell synthesis of membrane-associated proteins. Proc Natl Acad Sci U S A 88:9897, 1991
22. Michie HR, Manogue KR, Spriggs DR, Roux-Lombard P, J5 Study Group, Lambert P-H: Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 318:1481, 1988
23. Van Deventer SJH, Büller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic and complement pathways. Blood 76:2520, 1990
24. Schwager I, Jungi TW: Effect of human recombinant cytokines on the induction of macrophage procoagulant activity. Blood 83:152, 1994
25. Gregory SA, Kornbluth RS, Helin H, Remold HG, Edgington TS: Monocyte procoagulant inducing factor: A lymphokine involved in the T cell-instructed monocyte procoagulant response to antigen. J Immunol 137:3231, 1986
26. Raasveld MH, Bemelman FJ, Schellekens PT, van Diepen FN, van Dongen A, van Royen EA, Hack CE, ten Berge IJ: Complement activation during OKT3 treatment: A possible explanation for respiratory side effects. Kidney Int 43:1140, 1993
27. Law SK: C3 receptors on macrophages. J Cell Sci Suppl 9:67,1988
28. Parlevliet KJ, ten Berge IJ, Yong SL, Surachno J, Wilmink JM, Schellekens PT: In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants. J Clin Invest 93:2519, 1994
29. Waid TH, Lucas BA, Thompson JS, Brown SA, Munch L, Prebeck RJ, Jezek D: Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients. Transplantation 53:80, 1992
30. Anasetti C, Martin PJ, Storb R, Appelbaum FR, Beatty PG, Davis J, Doney K, Hill HF, Stewart P, Sullivan KM, Witherspoon RP, Thomas ED, Hansen Y: Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody. Transplantation 54:844, 1992
31. Knight RJ, Kurrle R, McClain J, Racenberg J, Baghdahsarian V, Kerman R, Lewis R, Van Buren CT, Kahan BD: Clinical evaluation of induction immunosuppression with a murine IgG2b monoclonal antibody (BMA 031) directed toward the human a/b-T cell receptor. Transplantation 57:1581, 1994
32. Abramowicz D, Norman DJ, Vereerstraeten P, Goldman M, De Pauw L, Vanherweghem JL, Kinnaert P, Kahana L, Stuart FP Jr, Thistlethwaite JR, Shield CF III, Monaco A, Wu SC, Haverty TP: OKT3 prophylaxis in renal grafts with prolonged cold ischemia times: Association with improvement in long term survival. Kidney Int (in press)